Susana González-Rámila1, Beatriz Sarriá1, Miguel A Seguido1, Joaquín García-Cordero1, Raquel Mateos1, Laura Bravo2. 1. Institute of Food Science, Technology and Nutrition (ICTAN-CSIC), Spanish National Research Council (CSIC), José Antonio Nováis 10, 28040, Madrid, Spain. 2. Institute of Food Science, Technology and Nutrition (ICTAN-CSIC), Spanish National Research Council (CSIC), José Antonio Nováis 10, 28040, Madrid, Spain. lbravo@ictan.csic.es.
Abstract
PURPOSE: This study aimed to assess the effect of dietary consumption of olive pomace oil (OPO) on blood lipids (primary outcome) and other cardiovascular disease (CVD) risk factors (blood pressure, inflammation and endothelial function as secondary outcomes). METHODS: A randomized, controlled, blind, crossover intervention was carried out in healthy and at-risk (hypercholesterolemic) subjects. Participants consumed daily 45 g of OPO or high-oleic acid sunflower oil (HOSO) as control oil during 4 weeks. RESULTS: OPO significantly reduced low-density lipoprotein cholesterol (LDL-C; P = 0.003) and apolipoprotein B (Apo B; P = 0.022) serum concentrations, and LDL/HDL ratio (P = 0.027) in healthy and at-risk volunteers. These effects were not observed with HOSO. Blood pressure, peripheral artery tonometry (PAT), endothelial function and inflammation biomarkers were not affected. CONCLUSIONS: Regular consumption of OPO in the diet could have hypolipidemic actions in subjects at cardiovascular risk as well as in healthy consumers, contributing to CVD prevention. CLINICAL TRIAL REGISTRY: NCT04997122, August 8, 2021, retrospectively registered.
PURPOSE: This study aimed to assess the effect of dietary consumption of olive pomace oil (OPO) on blood lipids (primary outcome) and other cardiovascular disease (CVD) risk factors (blood pressure, inflammation and endothelial function as secondary outcomes). METHODS: A randomized, controlled, blind, crossover intervention was carried out in healthy and at-risk (hypercholesterolemic) subjects. Participants consumed daily 45 g of OPO or high-oleic acid sunflower oil (HOSO) as control oil during 4 weeks. RESULTS: OPO significantly reduced low-density lipoprotein cholesterol (LDL-C; P = 0.003) and apolipoprotein B (Apo B; P = 0.022) serum concentrations, and LDL/HDL ratio (P = 0.027) in healthy and at-risk volunteers. These effects were not observed with HOSO. Blood pressure, peripheral artery tonometry (PAT), endothelial function and inflammation biomarkers were not affected. CONCLUSIONS: Regular consumption of OPO in the diet could have hypolipidemic actions in subjects at cardiovascular risk as well as in healthy consumers, contributing to CVD prevention. CLINICAL TRIAL REGISTRY: NCT04997122, August 8, 2021, retrospectively registered.
Authors: José M Santos-Lozano; Mirela Rada; José Lapetra; Ángeles Guinda; María C Jiménez-Rodríguez; José A Cayuela; Antonio Ángel-Lugo; Ángel Vilches-Arenas; Ana M Gómez-Martín; Manuel Ortega-Calvo; José M Castellano Journal: Diabetes Obes Metab Date: 2019-08-28 Impact factor: 6.577
Authors: Jeffrey T Kuvin; Ayan R Patel; Kathleen A Sliney; Natesa G Pandian; Jacob Sheffy; Robert P Schnall; Richard H Karas; James E Udelson Journal: Am Heart J Date: 2003-07 Impact factor: 4.749
Authors: María Valero-Muñoz; Beatriz Martín-Fernández; Sandra Ballesteros; Esther de la Fuente; José Carlos Quintela; Vicente Lahera; Natalia de las Heras Journal: Mol Nutr Food Res Date: 2013-09-04 Impact factor: 5.914